Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

被引：1
|
作者：
Venditti, Adriano [1 ]
Hou, Jing-Zhou [2 ]
Fenaux, Pierre [3 ]
Jonas, Brian A. [4 ]
Vrhovac, Radovan [5 ,6 ]
Montesinos, Pau [7 ]
Garcia, Jacqueline S. [8 ]
Rizzieri, David [9 ]
Thirman, Michael J. [10 ]
Kotey, Stanley [11 ]
Potluri, Jalaja [11 ]
Dhalla, Mazaher [11 ]
Pullarkat, Vinod [12 ]
机构：
[1] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy
[2] UPMC Hillman Canc Ctr, Lemieux Ctr Blood Canc, Hematol & BMT, Pittsburgh, PA USA
[3] Univ Paris, St Louis Hosp, Dept Hematol, Paris, France
[4] Univ Calif Davis, Div Malignant Hematol Cellular Therapy & Transpla, Dept Internal Med, Sch Med, Sacramento, CA USA
[5] Univ Hosp Ctr Zagreb, Dept Haematol, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Zagreb, Croatia
[7] Hosp Univ & Politecn La Fe, Valencia, Spain
[8] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[9] Novant Hlth Canc Inst, Winston Salem, NC USA
[10] Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL USA
[11] AbbVie Inc, N Chicago, IL USA
[12] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy
    Chow, Lydia D.
    Chen, Denaly
    Vergara-Lluri, Maria E.
    Tam, Eric
    Woan, Karrune
    Chaudhary, Preet M.
    Yaghmour, George
    Ladha, Abdullah
    BLOOD, 2022, 140 : 9027 - 9028
  • [22] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
  • [23] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy (vol 52, pg 29, 2022)
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (05) : 456 - 456
  • [24] Real-World Efficacy and Hematologic Toxicity of Azacitidine and Venetoclax in a Cohort of Elderly Patients Unfit for Intensive Chemotherapy With Newly Diagnosed Acute Myeloid Leukemia
    Wysoglad, Hubert
    Krawczyk, Katarzyna
    Ochrem, Bogdan
    Madry, Krzysztof
    Drozd-Sokolowska, Joanna
    Sacha, Tomasz
    Basak, Grzegorz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S294 - S294
  • [25] Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax plus Azacitidine Versus Intensive Chemotherapy
    Winters, Amanda C.
    Bosma, Grace
    Abbott, Diana
    Minhajuddin, Mohd
    Jordan, Craig
    Pollyea, Daniel A.
    Gutman, Jonathan A.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10): : 694.e1 - 694.e9
  • [26] Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
    Weinbergerova, Barbora
    Mayer, Jiri
    Kabut, Tomas
    Sperr, Wolfgang R.
    Stevkova, Jana
    Jonasova, Anna
    Cernan, Martin
    Herndlhofer, Susanne
    Oravcova, Iveta
    Sramek, Jiri
    Novak, Jan
    Stepanova, Radka
    Szotkowski, Tomas
    Drgona, Lubos
    Zak, Pavel
    Valent, Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 1746 - 1750
  • [27] The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine
    Doyel, Michael
    Bouligny, Ian Michael
    Murray, Graeme
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Thuy Ho
    Zacholski, Kyle
    Venn, Chad Michael
    Alnimer, Yanal Mufeed
    Wages, Nolan
    Grant, Steven
    Maher, Keri Renee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients
    Ibrahim, Ahmed
    Yousaf, Muhammad Abdullah
    Anwar, Zain
    Anum
    Batool, Maha
    Rehman, Mohammad
    Safdar, Omar A.
    Khattak, Zeeshan Ahmed
    Faraz, Fatima
    Khalid, Huma
    BLOOD, 2023, 142
  • [29] Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients
    Yu, Hong
    Wang, Chaomeng
    Lei, Yingying
    Li, Lijuan
    Wang, Huaquan
    Wang, Guojin
    Xing, Limin
    Guan, Jing
    Song, Jia
    Wu, Yuhong
    Liu, Hong
    Qu, Wen
    Wang, Xiaoming
    Shao, Zonghong
    Fu, Rong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [30] Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia
    Gibson, Amber
    Dickson, Samantha
    McCall, David
    Garcia, Miriam
    Connors, Jeremy
    He, Jiasen
    Roth, Michael
    Nunez, Cesar
    Cuglievan, Branko
    PEDIATRIC BLOOD & CANCER, 2024,
12345